Recently, it has been demonstrated that programmed death 1 (PD-1) and its receptors, including ligand-1 (PD-L1) and ligand-2 (PD-L2) are thought to be other effective therapeutic targets for malignant tumors. This evidence concerns the gene CD274 and cancer.